Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review

BACKGROUND: Rare cancers, as defined by the European Union, occur in fewer than 15 out of 100,000 people each year. The International Rare Cancer Consortium defines rare cancer incidence as less than six per 100,000 per year. There is a growing number of reports of the efficacy of immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Consoli, Francesca, Ghidini, Antonio, Perego, Gianluca, Luciani, Andrea, Mercurio, Paola, Berruti, Alfredo, Grisanti, Salvatore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488393/
https://www.ncbi.nlm.nih.gov/pubmed/34616395
http://dx.doi.org/10.3389/fimmu.2021.720748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488393/
https://www.ncbi.nlm.nih.gov/pubmed/34616395
http://dx.doi.org/10.3389/fimmu.2021.720748

Ejemplares similares